Icatibant (Firazyr®, Shire, Zug, Switzerland) is a subcutaneously administered bradykinin B2 receptor antagonist for the treatment of acute angioedema attacks in adults with type 1 or 2 C1-INH-HAE. Here, BDKRB2 is linked to hereditary angioedema.